Giorgia Guglielmi
The interaction between newborns’ epithelia and the microbiota is crucial to the balance of the oral mucosa and it can have long-term health consequences.
TCGA allows to explore the role of tissue-resident microbiota in various cancer types and identifying predictive microbial biomarkers.
Immune responses to the gut microbiota can be used as biomarkers of clinical course in IBD or as targets for the treatment or prevention of the condition.
Decreased microbial diversity and increased abundance of Firmicutes phylum in the respiratory tract may be associated with an increased risk of lung cancer.
The findings suggest that delivery mode, rather than birth canal exposure, has a strong influence on the composition of the infant microbiota.
Modulating the gut microbiota could help to increase Plasmodium-specific immunity, thus reducing disease severity and malaria-associated mortality.
Researches have found that MDD is characterized by disturbances in the gut microbiota and may allow clinicians to better diagnose it.
A two-pronged treatment strategy — consisting of an engineered peptide and an FDA-approved drug — could help to reduce gut inflammation.
The current knowledge of the gut-liver axis in NAFLD may lead to the development of microbiota-based personalized approaches for managing the condition.
A study published in Nature suggests new approaches to improve BMTs as well as treatments for immune-mediated diseases by regulating the gut microbiota.
